Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P61278 (
somatostatin
)
22,083
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The patient, who died at 23 years of age, was first diagnosed when she was 12 year old as having a
dopa-responsive dystonia
with decreased concentrations of monoamine metabolites in the cerebrospinal fluid. Also the concentrations of other neurotransmitters including
somatostatin
, substance P and metenkefalin were lowered indicating a more widespread damage of the cerebral neurotransmitter systems. At autopsy the brain was essentially intact except for pronounced gliosis and extreme loss of melanotic nerve cells in the substantia nigra. Several remaining nerve cells showed the presence of Lewy bodies.
...
PMID:Dopa-responsive dystonia with depigmentation of the substantia nigra and formation of Lewy bodies. 146 45
The primary treatment for non-functioning pituitary tumors (NFPTs) is surgery, but it is often unsuccessful. Previous studies have reported that NFPTs express receptors for
somatostatin
(SST
1-5
) and dopamine (DRDs) providing a rationale for the use of dopamine agonists and
somatostatin
analogues. Here, we systematically assessed SST
1-5
and DRDs expression by real-time quantitative PCR (RT-qPCR) in a large group of patients with NFPTs (
n
= 113) and analyzed their potential association with clinical and molecular aggressiveness features. SST
1-5
expression was also evaluated by immunohistochemistry. SST
3
was the predominant SST subtype detected, followed by SST
2
, SST
5
, and SST
1
. DRD2 was the dominant
DRD
subtype, followed by DRD4, DRD5, and DRD1. A substantial proportion of NFPTs displayed marked expression of SST
2
and SST
5
. No major association between SST
s
and DRDs expression and clinical and molecular aggressiveness features was observed in NFPTs.
...
PMID:Quantitative Analysis of Somatostatin and Dopamine Receptors Gene Expression Levels in Non-functioning Pituitary Tumors and Association with Clinical and Molecular Aggressiveness Features. 3297 45
